A study to determine the optimum dose of metaraminol required to increase blood pressure by 25% during subarachnoid anaesthesia

Anaesth Intensive Care. 1999 Apr;27(2):170-4. doi: 10.1177/0310057X9902700207.

Abstract

We studied dosage optimization for metaraminol when managing hypotension during subarachnoid anaesthesia. Twenty patients aged 53 to 84 years, were recruited. Non-invasive blood pressure (BP) and heart rate were recorded one-minutely. A series of four i.v. metaraminol boluses (0.25 to 1.0 mg per 50 kg adult) were administered. From individual patient time plots of BP predicted dosages for a 25% elevation in BP were estimated. Dose-related elevations in systolic BP [mean (SD)] occurred following dosages of 0.5 mg [25 (11)%] and 1.0 mg [50 (23)%]. Similar elevations occurred in mean and diastolic BP. Overall estimated dosage (median) to produce a 25% elevation in systolic BP was 0.5 mg (per 50 kg adult). However, individual patient responses varied (10-90th centiles = 0.23 to 0.80 mg). Thus, we now recommend a starting dose of 0.25 mg, increasing to 0.5 mg if necessary, to treat hypotension (25% decrease in systolic BP) during subarachnoid anaesthesia.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anesthesia, Conduction*
  • Blood Pressure / drug effects*
  • Dose-Response Relationship, Drug
  • Electrocardiography
  • Female
  • Heart Rate / drug effects
  • Humans
  • Hypotension / drug therapy
  • Infusions, Intravenous
  • Male
  • Metaraminol / administration & dosage*
  • Middle Aged
  • Monitoring, Intraoperative
  • Subarachnoid Space
  • Vasoconstrictor Agents / administration & dosage*

Substances

  • Vasoconstrictor Agents
  • Metaraminol